Introduction {#s1}
============

Newly transcribed messenger RNAs undergo processing steps such as capping, splicing and polyadenylation to derive mature RNAs for export and translation (Hocine et al., [@B8]). The splicing process, as accomplished by the spliceosome machine, can produce multiple alternative products, which is a well-known phenomena called alternative splicing (AS) (Lee and Rio, [@B12]). Since its first discovery in 1977, many classical studies have characterized its widespread participation in biological processes such as cell proliferation, apoptosis, angiogenesis, neuronal functions, and transcriptional regulation (Kelemen et al., [@B10]). Deregulation of AS also contributes to human diseases and various aspects of cancer development (David and Manley, [@B3]; Scotti and Swanson, [@B17]).

To systematically characterize the extensive cancer-associated AS perturbations, it is essential to design effective analytic strategies suitable for the ever-growing cancer genomic datasets, largely from projects such as The Cancer Genome Atlas (TCGA). Several approaches have already been taken previously. One of the most popular approaches is the event-driven approach, which aimed to detect individual events that are correlated with cancer or prognosis (Danan-Gotthold et al., [@B2]; Dvinge and Bradley, [@B4]; Shen et al., [@B20]). A second approach focuses on the splicing machinery side and tries to determine the deregulation of splicing factors in tumors (Sebestyén et al., [@B18]; Sveen et al., [@B24]; Seiler et al., [@B19]). Since these approaches emphasized different aspects of the AS perturbations, several recent studies have been linking the splicing factors and events together to identify AS deregulation and the corresponding functional impacts (Li et al., [@B13]; Kahles et al., [@B9]). However, this approach may oversee the vast majority of perturbed splicing events that are not easily explained by the few known regulatory factors (Li et al., [@B13]). Moreover, these studies essentially relied on single-event analysis, and have missed the inter-event linkages which could be equally important to fully understand cancer-specific AS perturbations. To complement these analyses, a fully network-based approach is needed to capture the concurrent perturbation patterns of cancer-associated AS. In addition, such an approach might also discover more robust AS patterns in one or multiple cancer types.

We carried out an extensive analysis of AS events and their interactions in different cancer types. For each cancer type, a network of cancer-associated events is reconstructed. To uncover the potential modularized control in these splicing networks, a random walk-based community identification algorithm is employed. These analyses have revealed representative splicing modules in each type of cancers, and a number of them are prognosis-relevant and involved in cancer-related functional processes. Finally, our work supports the unique value of an splicing network-based approach in understanding cancer splicing deregulation.

Materials and Methods {#s2}
=====================

Data Sets and Processing
------------------------

Splicing data have been downloaded from the TCGASpliceSeq database (Ryan et al., [@B16]). Clinical information is from the GDC TCGA project. Splicing events that failed to be quantified \>10% in normal samples or \>1% in cancer samples were filtered without further use. Cancer samples with \>0.1% missing data were also removed. The remaining missing values were imputed with the Bioconductor impute package.

Network Reconstruction and Module Identification
------------------------------------------------

For each cancer type, Pearson correlation coefficients among splicing events were computed between each pair of the differentially spliced events (Wilcoxon signed-rank test FDR \<0.1, \|delta PSI\|\>0.1), and were used as edge weights in the reconstructed undirected graph. The Pons-Lapaty random walk algorithm (step = 4) was used to partition the weighted graph. The identified modules from each cancer type were named according to the order of module sizes (from larger to smaller). So M1 is always at least as large as M2, and M2 at least as large as M3, etc.

Overall and Progression-Free Survival Analysis
----------------------------------------------

Module scores are averaged from all splicing events in each sample, with normal sample PSI values used as references and subtracted. Thus, the score measures how strong the module is perturbed in one cancer sample. To ensure robustness, both the average and median scores have been calculated. Overall survival (OS) and progression-free intervals (PFI) are respectively categorized for testing with module scores. The Kaplan-Meier survival curves are fitted and compared between samples with a higher vs. a lower module score using the Log-rank test. Hazard ratios and confidence intervals are estimated from the Cox proportional regression model. In total, 13 modules were found to be significantly correlated to either OS (10 modules) or PFI (8 modules). Of these, 5 modules were commonly significant in both OS and PFI. In addition, 2 Lung squamous cell carcinoma (LUSC) modules were nearly significant in OS and also included as candidates. Therefore, 15 modules were retained after filtering with OS and PFI analyses.

Functional Enrichment Analyses
------------------------------

Gene ontology (GO) enrichment was used to assess the functional properties of each module. The enrichment was determined by the Fisher\'s exact test method. For all significant GO terms, careful manual inspection and curation were performed to find the most relevant and biologically important functions, which is often a subset of the significant terms.

Results {#s3}
=======

Splicing Network-Based Flowchart for Identifying Prognosis-Relevant Splicing Modules
------------------------------------------------------------------------------------

The main analytic flowchart consist of six steps ([Figure 1](#F1){ref-type="fig"}): (1) Collection of annotated events from the TCGASpliceSeq database across 33 cancer types. The splicing classes included are exon skipping (ES), retention of introns (RI), alternative donor (AD), alternative acceptor (AA), mutually exclusive exons (ME), alternative terminator (AT). The numbers of quantified events were found in at least 99% of the samples in each cancer type range from 21129 to 43937 across the cancer types. (2) Differential splicing events between cancer samples and adjacent normal samples were identified for 16 cancer types with at least 10 normal samples. The Wilcoxon signed-rank test was used for testing. The number of differential events obtained ranges from 228 in ESCA to 1133 in LUSC. (3) Reconstruction of splicing network for each cancer type, with Pearson correlation coefficient-based similarity linkages. Pearson and Kendall correlation coefficients showed a good consistency in subsequent community detection, confirming the reliability of this procedure ([Figure S1](#SM1){ref-type="supplementary-material"}). (4) Network module identification with the Pons-Lapaty algorithm which is based on random walks in 3--5 steps to measure vertex distances for hierarchical clustering and subsequent modularity-optimized graph partition (Pons and Latapy, [@B15]). (5) Modules are then scored with the averaged splicing deregulation between each cancer sample and the normal samples, which provide a reasonable quantification of module-level perturbation across cancer samples. (6) Prognosis analyses for each module and its corresponding cancer type. [Figure 1](#F1){ref-type="fig"} shows a schematic diagram of these steps.

![Flowchart of analyses.](fgene-10-00246-g0001){#F1}

Cancer Splicing Networks and Modules for TCGA Cancer Types
----------------------------------------------------------

We reconstructed splicing networks for each cancer type with at least 10 normal samples on differential events. There are 16 cancer types that bypass the above criteria, namely: Bladder urothelial carcinoma (BLCA), Breast invasive carcinoma (BRCA), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Head and Neck squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Prostate adenocarcinoma (PRAD), Rectum adenocarcinoma (READ), Stomach adenocarcinoma (STAD), Thyroid carcinoma (THCA), and Uterine Corpus Endometrial Carcinoma (UCEC). The number of modules identified with the Pons-Lapaty algorithm varied between 2 and 5 for these cancer types. The visualized inspection revealed quite clear network partitions ([Figure 2](#F2){ref-type="fig"}). In total, 51 modules were identified, and the number of events and genes in each module can be found in [Table 1](#T1){ref-type="table"} and [Table S1](#SM3){ref-type="supplementary-material"}. For example, the KIRC_M1 module consisted of 710 events in 630 genes, with 41 AA events, 36 AD events, 229 AT events, 210 ES events, 3 ME events, and 191 RI events.

![Splicing networks for different cancer types. Modules identified by random walks are highlighted in different colors.](fgene-10-00246-g0002){#F2}

###### 

A list of 51 cancer splicing modules.

  **Module**   **Genes**   **Events**   **AA**   **AD**   **AT**   **ES**   **ME**   **RI**
  ------------ ----------- ------------ -------- -------- -------- -------- -------- --------
  BLCA_M1      302         332          22       19       130      73       0        88
  BLCA_M2      188         191          4        0        152      30       1        4
  BLCA_M3      118         119          8        7        91       12       0        1
  BLCA_M4      104         111          3        4        73       26       1        4
  BRCA_M1      239         257          14       8        137      73       1        24
  BRCA_M2      216         221          8        8        158      37       2        8
  BRCA_M3      107         121          6        5        54       40       1        15
  BRCA_M4      51          52           2        2        25       19       1        3
  COAD_M1      91          94           2        0        67       15       0        10
  COAD_M2      57          66           2        1        48       8        1        6
  COAD_M3      56          56           1        4        49       1        0        1
  COAD_M4      42          43           2        3        16       6        0        16
  ESCA_M1      132         141          5        13       60       32       0        31
  ESCA_M2      86          87           1        8        64       12       1        1
  HNSC_M1      200         220          14       9        93       53       1        50
  HNSC_M2      159         165          3        4        126      28       0        4
  HNSC_M3      116         127          7        2        84       29       0        5
  KICH_M1      449         490          23       23       224      125      1        94
  KICH_M2      363         383          10       19       232      90       5        27
  KICH_M3      272         290          7        17       164      78       2        22
  KIRC_M1      630         710          41       36       229      210      3        191
  KIRC_M2      279         286          1        3        243      30       5        4
  KIRC_M3      104         137          8        5        80       38       2        4
  KIRP_M1      442         483          34       29       189      110      0        121
  KIRP_M2      283         324          6        8        262      33       2        13
  LIHC_M1      163         169          5        7        105      28       1        23
  LIHC_M2      148         154          6        4        118      21       0        5
  LIHC_M3      49          53           2        4        30       8        0        9
  LIHC_M4      42          43           2        1        36       3        0        1
  LUAD_M1      305         321          11       4        212      79       4        11
  LUAD_M2      217         230          13       21       71       64       0        61
  LUAD_M3      192         196          7        7        132      42       3        5
  LUSC_M1      526         574          16       16       312      208      5        17
  LUSC_M2      397         428          20       38       235      113      6        16
  LUSC_M3      281         333          19       24       128      81       1        80
  PRAD_M1      202         220          11       9        82       51       0        67
  PRAD_M2      105         105          1        1        80       19       0        4
  PRAD_M3      8           11           0        0        11       0        0        0
  READ_M1      186         199          11       17       106      31       1        33
  READ_M2      132         154          10       7        66       29       1        41
  READ_M3      122         131          3        1        67       52       0        8
  STAD_M1      141         164          11       13       37       41       0        62
  STAD_M2      123         130          9        10       51       51       2        7
  STAD_M3      108         112          1        3        71       35       1        1
  STAD_M4      34          34           0        0        25       8        0        1
  STAD_M5      17          24           1        1        16       4        0        2
  THCA_M1      157         168          0        2        128      22       0        16
  THCA_M2      149         151          4        2        114      17       0        14
  UCEC_M1      292         302          7        5        244      31       2        13
  UCEC_M2      206         210          4        4        172      14       0        16
  UCEC_M3      117         121          4        7        65       27       1        17

*AA, alternative acceptor; AD, alternative donor; AT, alternative terminator; ES, exon skipping; ME, mutually exclusive exons; RI, retention of introns. For cancer type abbreviations, see text*.

Overall and Progression-Free Survival Analyses for Cancer Splicing Modules
--------------------------------------------------------------------------

Since the motivation of this study is to discover prognosis-related splicing modules, we quantified module scores in each cancer sample and test associations between module scores and patient survival. Both the average score and median score were computed and assessed for prognosis correlation, and a very good consistency was found ([Figure S2](#SM2){ref-type="supplementary-material"}), indicating robustness of the module scoring procedure. At a 0.05 significance level, Log-rank tests identified 10 prognosis-related modules: BLCA_M1, BLCA_M2, KIRC_M1, KIRC_M2, LIHC_M1, LIHC_M2, LUAD_M1, LUAD_M3, PRAD_M1, and UCEC_M3 ([Table 2](#T2){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}). Two additional modules, the LUSC_M2 (*P* = 0.0595, HR = 0.75 with a confidence interval 0.55--1.01) and the LUSC_M3 (*P* = 0.099, HR = 0.77 with a confidence interval 0.57--1.05), are close to the significance level, and therefore are still likely to be potential prognosis biomarkers ([Figure 3E](#F3){ref-type="fig"}). Notably, LUSC_M2 contains a ME event on the known LUSC amplification gene FGFR1 (exons 12.1:12.2 vs. exon 13), which could be functionally important in LUSC (Weiss et al., [@B26]; Heist et al., [@B6]).

###### 

Cancer splicing modules correlated with prognosis.

  **Module**   **OS_HR**            **OS_P**   **PFS_HR**          **PFS_P**   **Function**
  ------------ -------------------- ---------- ------------------- ----------- ---------------------------------------------------------------------
  BLCA_M1      0.57 (0.41--0.78)    0.00052    0.67 (0.48--0.91)   0.011       Stem cell proliferation; EMT
  BLCA_M2      1.78 (1.29--2.48)    0.00044    1.42 (1.04--1.95)   0.027       Microtubule bundle; actin filament polymerization
  BLCA_M4      0.75 (0.54--1.03)    0.076      0.70 (0.51--0.97)   0.029       Cell junction; Rac and Ras signaling
  KIRC_M1      2.04 (1.46--2.84)    2E−05      1.24 (0.89--1.74)   0.2         mRNA splicing and export; transcription termination
  KIRC_M2      0.50 (0.36--0.70)    3.5E−05    0.77 (0.55--1.08)   0.12        Drug metabolism; PI3K signaling; amino acid metabolism
  LIHC_M1      2.06 (1.41--3.02)    0.00013    1.32 (0.96--1.82)   0.085       ERK1/2 signaling; organ growth; PI3K signaling
  LIHC_M2      0.50 (0.34--0.73)    0.00023    0.79 (0.57--1.08)   0.14        ERK1/2 signaling; stem cell proliferation; embryonic epithelium
  LUAD_M1      0.63 (0.45--0.87)    0.0043     0.74 (0.55--1.01)   0.054       PKC signaling; VEGF and lymph vessel development
  LUAD_M3      1.86 (1.34--2.58)    0.00018    1.42 (1.05--1.93)   0.023       Mitosis; double-strand break repair
  LUSC_M2      0.75 (0.55--1.01)    0.059      0.80 (0.56--1.15)   0.22        Phospholipase activity; formation of primary germ layer
  LUSC_M3      0.77 (0.57--1.05)    0.099      0.98 (0.69--1.41)   0.93        EMT; GPCR signaling; double--strand break repair
  PRAD_M1      6.42 (0.78--52.60)   0.049      1.80 (1.16--2.79)   0.0081      Calcium ion homeostasis; muscle contraction; mesoderm morphogenesis
  PRAD_M2      0.42 (0.08--2.19)    0.29       0.52 (0.33--0.81)   0.0032      Calcium ion homeostasis; cell-cell adhesion
  THCA_M1      1.21 (0.45--3.23)    0.7        0.55 (0.31--0.99)   0.041       Stem cell proliferation
  UCEC_M3      1.81 (1.15--2.84)    0.0087     1.66 (1.12--2.47)   0.01        Type I interferon production; DNA duplex unwinding

*OS, overall survival; PFS, progression-free survival; HR, hazard ratio; P, Log-rank test p-value*.

![Overall survival analyses for splicing modules. Red curves are with a high module score, and blue curves with a low module score. **(A)** BLCA_M1; **(B)** KIRC_M2; **(C)** LIHC_M1; **(D)** LUAD_M1; **(E)** LUSC_M2; **(F)** UCEC_M3.](fgene-10-00246-g0003){#F3}

Besides overall survival (OS) that reflects a long-term prognosis, it is often of interest to evaluate short-term effects on disease progression. Therefore, to further capture more prognosis-related modules, we also tested the correlation between module scores and progression-free intervals (PFI). This analysis returned 8 significant modules (*P* ≤ 0.05), namely, BLCA_M1, BLCA_M2, BLCA_M4, LUAD_M3, PRAD_M1, PRAD_M2, THCA_M1, and UCEC_M3 ([Table 2](#T2){ref-type="table"}, [Figure 4](#F4){ref-type="fig"}). Note that BLCA_M4 is also marginally significant in OS analysis (*P* = 0.076, HR = 0.75 with a confidence interval of 0.54--1.03), while PRAD_M2 (OS *P* = 0.29) and THCA_M1 (OS *P* = 0.7) are only significant in PFI analysis. Five modules are strictly significant in both the OS and PFI settings (BLCA_M1, BLCA_M2, LUAD_M3, PRAD_M1, and UCEC_M3), and interestingly, their HR ratios in these two settings are in a similar trend, either both reducing or both increasing malignancy risks. BLCA_M1 lowers both the death risk (0.57, 0.41--0.78) and the disease progression risk (0.67, 0.48--0.91); BLCA_M2 increases both the death risk (1.78, 1.29--2.48) and the progression risk (1.42, 1.04--1.95); LUAD_M3 also increases both risks (1.86, 1.34--2.58 and 1.42, 1.05--1.93, respectively); PRAD_M1 also increases both risks (6.42, 0.78--52.60 and 1.80, 1.16--2.79, respectively); UCEC_M3 similarly increases both risks (1.81, 1.15--2.84 and 1.66, 1.12--2.47, respectively). These strongly indicate the consistency of splicing modules as potential prognosis biomarkers, suggesting underlying functional involvement of these modules in their corresponding cancer types.

![Progression-free survival analyses for splicing modules. Red curves are with a high module score, and blue curves with a low module score. **(A)** BLCA_M4; **(B)** LUAD_M3; **(C)** PRAD_M1; **(D)** PRAD_M2; **(E)** THCA_M1; **(F)** UCEC_M3.](fgene-10-00246-g0004){#F4}

Cancer Splicing Modules Are Enriched for Critical Biological Functions
----------------------------------------------------------------------

The above analyses yielded 15 modules with potential prognosis relevance ([Table 2](#T2){ref-type="table"}). To characterize the functional properties of each splicing module, GO enrichment analysis was performed on the 15 modules. The major functional implications of each module were manually examined and curated from the enrichment results ([Table 2](#T2){ref-type="table"}). Since nearly all genes transcribed in the genome, including many long non-coding genes, underwent alternative splicing, typically very few events could drive strong functional changes, and the majority of alternative splicing events at most function as weaker modifiers. Surprisingly, we found that the 15 modules, when compared to the splicing events catalog, showed very strong enrichment of important biological functions, such as stem cell proliferation and epithelial-mesenchymal transition (EMT), (BLCA_M1, LIHC_M2, LUSC_M1, THCA_M1, THCA_M2, UCEC_M2), cell cycle control (BRCA_M1, BRCA_M2, COAD_M4, KICH_M1, STAD_M1), DNA repair or regulation (COAD_M3, ESCA_M2, HNSC_M3, KICH_M1, LUAD_M3, LUSC_M3, UCEC_M3), developmental cell growth (BRCA_M4, COAD_M1, LIHC_M1, LIHC_M3, READ_M1, READ_M2, STAD_M2, STAD_M3), receptor or kinase signaling pathways (BLCA_M4, HNSC_M1, KICH_M1, KIRC_M2, KIRP_M1, KIRP_M2, LIHC_M1, LIHC_M2, LUAD_M1, LUAD_M2, LUSC_M1, LUSC_M3, READ_M2), VEGF-mediated vessel development (LUAD_M1, LUSC_M1) ([Table 2](#T2){ref-type="table"}). Among these major functions, EMT is required for cancer invasion and metastasis, which is closely related to cancer mortalities and prognosis (Singh and Settleman, [@B21]). The important EMT-related gene modulated in BLCA and LIHC is FGFR2, which regulates mesenchymal condensation in BLCA (Chaffer et al., [@B1]). Targeting FGFR signaling through splicing factors might expand the current toolkits (Touat et al., [@B25]). Vessel development controlled by VEGF signaling is another pathway directly involved in cancer metastasis and patient survival (Stacker et al., [@B22]; Su et al., [@B23]). Both VEGFA and its receptor FLT4 (VEGFR-3) were altered during splicing in lung cancers LUAD and LUSC, which might modulate angiogenesis through splicing control. In summary, these suggest that the splicing network-based module identification approach taken in this study was powerful enough to extract the few critically functional events from a much larger splicing background.

Splicing Modules Across Cancer Types Reveal Pan-Cancer Signatures
-----------------------------------------------------------------

Having obtained those functionally coherent modules, we next asked whether it would be helpful to explore the pan-cancer landscape at the module level. Hierarchical clustering of cancer types with the 51 modules revealed a clear pattern that is closely related to tissue origins ([Figure 5A](#F5){ref-type="fig"}). Lung cancers (LUAD, LUSC), colon cancers (COAD, READ), gynecological cancers (BRCA, UCEC), kidney, and prostate cancers (KIRC, KIRP, KICH, PRAD) each are clustered in a tissue origin manner. This is actually consistent with a recent pan-cancer analysis using multi-platform integrative clustering (Hoadley et al., [@B7]), suggesting that splicing events can also be useful for cancer classification and subtyping.

![**(A)** Hierarchical clustering of cancer types by 51 splicing modules. **(B)** Heatmap of module scores in each cancer type. "+" and "--" respectively denote that for ≥80% samples in the cancer type are with a higher and lower module score than normal samples. "\*\*" denotes the module are consistently "+" or "--" in ≥15/16 cancer types.](fgene-10-00246-g0005){#F5}

Due to the intra-type and between-type heterogeneity of cancers, it is important to know which of the splicing modules are shared by multiple cancer types and which modulesare restricted to one or few cancer types. We summarized the scores for each module in the cancer samples and categorized them by cancer type ([Figure 5B](#F5){ref-type="fig"}). The diagonal line here reflects the score of modules in their corresponding cancer types, while the off-diagonal regions depicts their pan-cancer potential. Although a few modules from kidney and liver cancers show a strong cancer type specificity, and largely not perturbed in other types (KICH_M3, LIHC_M3, LIHC_M4), many other modules display strong pan-cancer perturbation patterns, suggesting their wider involvement in most cancer types. With a strict criteria (perturbation found in at least 15/16 cancer types), we found that 13/51 modules are highly common across different cancer types (marked with ^\*\*^, [Figure 5B](#F5){ref-type="fig"}), again suggesting that the modules identified with splicing network analysis are highly informative and important.

Discussion {#s4}
==========

Although AS has been identified and studied for many years, the full regulation pattern of these many AS events within and across cancer types are still not completely understood. Previous studies have taken advantage of single-event analyses and linked splicing to splicing factors as well as the cis-elements. Very recently, an interesting study sets out to determine the involved of spliceosome RNAs in cancer-specific AS regulation (Dvinge et al., [@B5]).

In this study, we have taken a novel approach that emphasizes the inter-event correlations and uncovers the modularized perturbation of splicing events in cancers. Previous studies have not emphasized the modularized control of splicing events, which according to our study is quite important. Indeed, a relatively small number of functionally important and prognosis-relevant modules have been successfully identified, with some of them being common across cancer types and others being more specific to one or few cancer types, indicating that our approach is both powerful and useful.

To focus on the more typical AS classes, we have not considered alternative promoters in this study, as their regulation are more relevant to transcriptional factors, enhancers or even epigenetic modifications (Maunakea et al., [@B14]; Kowalczyk et al., [@B11]). Nonetheless, it would be interesting to investigate the possibility of combining transcriptional events and splicing events in the future, as co-transcriptional splicing has already been proposed and supported by various studies. This might serve as a plausible framework for those interactions (Lee and Rio, [@B12]).
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Comparison of Pearson and Kendall correlation coefficients on network and module detection. NMI (normalized mutual information) and ARI (adjusted Rand index) are used to evaluate consistency.
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Consistency between average and median module scores on survival analyses. **(Left)** OS analysis. **(Right)** PFI analysis. Each circle or "+" refers to a module.
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Detailed splicing events within each of the 51 splicing modules. Each event is named as "gene::eventID::eventType".
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